ProKidney Corp. - Class A Ordinary Shares PROK 深 沪
等待开盘 12-16 09:30:00 美东时间
2.08
-0.130
-5.88%
华盛通- 最 高2.21
- 今 开2.21
- 成交量 133.46万股
- 最 低 2.06
- 昨 收 2.21
- 总市值 2.81亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 0.4603
- 委 比 69.16%
- 总股本 1.35亿
- 历史最高 14.19
- 量 比 1.32
- 振 幅 6.79%
- 历史最低 0.4603
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the
11-11 05:36
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
A Phase 2 REGEN-007 trial demonstrated that rilparencel, a cell therapy, significantly slowed chronic kidney disease (CKD) progression in diabetic patients. Group 1 showed a 78% improvement in eGFR slope, with no serious adverse events. Phase 3 PROACT 1, which uses eGFR slope as a surrogate endpoint, has enrolled over half its required participants, with topline results expected in Q2 2027. Rilparencel is the first cell therapy in a Phase 3 trial...
11-06 16:00
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
ProKidney Corp. will present two posters at the American Society of Nephrology's Kidney Week 2025 in Houston, TX, on November 6-9: one on the Phase 2 REGEN-007 study results for renal autologous cell therapy in diabetes and CKD, and another on the inflammatory profile of rilparencel. The posters will be available on the company’s website post-event. ProKidney focuses on developing cellular therapies for chronic kidney disease, with its lead candi...
10-20 11:30
ProKidney Sells Greensboro Property for $19.1 Million
ProKidney ( ($PROK) ) has issued an update. ProKidney Corp. announced that on O...
10-18 05:00
ProKidney Corp. Signs New $19.1M Agreement To Sell Greensboro, NC Property After Prior Deal Termination
As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC ("Acquisition Sub"), entered into a purchase and sale agreement with
10-18 04:41
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.
10-02 23:32
美股牛股 | 网红股OpenDoor一夜飙升近80%！公司高管团队调整
网红股OpenDoor一夜飙升近80%！公司高管团队调整；传埃里森家族正筹备收购，华纳兄弟探索频道大涨超29%>>
09-12 14:23
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney Corp., a leader in cellular therapeutics for chronic kidney disease, announced that senior management will participate in two upcoming healthcare conferences: the Citi Biopharma Back to School Conference in Boston on September 3, 2025, and the Morgan Stanley Global Healthcare Conference in New York on September 8, 2025. Both events will feature fireside chat sessions available via live webcast. Additional details, including webcast link...
08-27 11:30
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14%
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
08-19 23:53
Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
07-17 23:52
